These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 21670452

  • 1. Molecular selection trumps clinical selection.
    Shepherd FA.
    J Clin Oncol; 2011 Jul 20; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract] [Full Text] [Related]

  • 2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.
    J Clin Oncol; 2011 Jul 20; 29(21):2866-74. PubMed ID: 21670455
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.
    N Engl J Med; 2009 Sep 03; 361(10):947-57. PubMed ID: 19692680
    [Abstract] [Full Text] [Related]

  • 4. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.
    J Clin Oncol; 2010 Feb 10; 28(5):744-52. PubMed ID: 20038723
    [Abstract] [Full Text] [Related]

  • 5. Histology matters: individualizing treatment in non-small cell lung cancer.
    Neal JW.
    Oncologist; 2010 Feb 10; 15(1):3-5. PubMed ID: 20086166
    [Abstract] [Full Text] [Related]

  • 6. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE, Ramalingam SS.
    Lancet Oncol; 2010 Jun 10; 11(6):500-1. PubMed ID: 20493770
    [No Abstract] [Full Text] [Related]

  • 7. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
    Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.
    Asia Pac J Clin Oncol; 2012 Sep 10; 8(3):232-43. PubMed ID: 22897752
    [Abstract] [Full Text] [Related]

  • 8. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK, McNeill JD, Judy B, Bauml J, Evans TL, Cohen RB, Langer C, Vachani A, Aggarwal C.
    Oncotarget; 2015 Oct 06; 6(30):30287-94. PubMed ID: 26471290
    [Abstract] [Full Text] [Related]

  • 9. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G, Xie X, Sun D, Geng J, Fu F, Zhang L, Wang H.
    Int J Clin Exp Pathol; 2015 Oct 06; 8(7):8603-6. PubMed ID: 26339441
    [Abstract] [Full Text] [Related]

  • 10. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group.
    N Engl J Med; 2010 Jun 24; 362(25):2380-8. PubMed ID: 20573926
    [Abstract] [Full Text] [Related]

  • 11. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
    Saijo N, Takeuchi M, Kunitoh H.
    Nat Rev Clin Oncol; 2009 May 24; 6(5):287-94. PubMed ID: 19390555
    [Abstract] [Full Text] [Related]

  • 12. Clairvoyance or reliable prediction of the future?
    van Zandwijk N, van de Vijver MJ.
    Ann Oncol; 2007 Mar 24; 18(3):407-8. PubMed ID: 17322538
    [No Abstract] [Full Text] [Related]

  • 13. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C.
    JAMA Oncol; 2015 Sep 24; 1(6):838-40. PubMed ID: 26181671
    [No Abstract] [Full Text] [Related]

  • 14. Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives.
    Vilmar AC, Sorensen JB.
    Eur Respir Rev; 2011 Mar 24; 20(119):45-52. PubMed ID: 21357891
    [Abstract] [Full Text] [Related]

  • 15. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X.
    Clin Lung Cancer; 2015 Sep 10; 16(5):e25-35. PubMed ID: 25801750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preliminary activity of capmatinib with gefitinib in NSCLC.
    Burki TK.
    Lancet Oncol; 2018 Oct 10; 19(10):e517. PubMed ID: 30197173
    [No Abstract] [Full Text] [Related]

  • 19. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E, Pisapia P, Feliciano S, Vigliar E, Marano A, De Luca C, Malapelle U, Troncone G, Bellevicine C.
    J Clin Pathol; 2017 Sep 10; 70(9):798-802. PubMed ID: 28363898
    [Abstract] [Full Text] [Related]

  • 20. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 10; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.